Understanding CML: Your Journey from Diagnosis to Treatment

Opinion
Video

A panel of experts on introduce a discussion on chronic myeloid leukemia (CML) with an overview of the disease, focusing on its subtypes and characteristics.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • Please provide some background on CML. What are the different subtypes of CML and how do they differ in terms of presentation and management?
  • Can you explain the typical prognosis and disease course for someone diagnosed with CML? How do you educate newly diagnosed patients on what to expect?
Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.